OUR STRATEGY TO
SUSTAIN VALUE

Given the healthy cash generation in this and prior periods, the Group now has significant resources available for future growth and development.

Our strategy

STABILISE AND
BUILD ON THE
FOUNDATION		 A relentless focus on
customer
service		   Strict cost
control		   Focused investment
in sales and marketing
of our major brands,
thereby continuing to
grow our
market share		   Extracting
manufacturing
efficiencies
and increasing
throughput at Wadeville
and Clayville		   Maintaining
full regulatory
compliance
in the factories and
distribution centres, and
no product recalls		   Reinforcing the culture of
responsibility,
accountability
and fun
at work
         

GROWTH AND EXPANSION

Acquisitions

Brands, portfolios and businesses, with a primary focus on non-regulated portfolios in home care, personal care and baby care. Searching for acquisitions of brands for the OTC Division in the core categories of analgesia, colds & flu and anti-histamines. In the Prescription Division, acquisitions of tail-end or nonpromoted products of multinationals. In the Hospital Division the focus is on investigating categories in which we do not currently operate.

  
Partnerships

Extending our MNC relationships into distribution activities. In the Prescription Division, pursuing generic partnership relationships to improve our product offering and obtaining clone molecules and co-promotion opportunities from our MNC partners. In the Hospital Division, investigating agency or licence agreements with companies whom we do not currently partner, in categories where we are not active.

  
New customers & sales channels

These include further contract manufacturing opportunities in the OTC and Prescription Divisions. Further extending our detailing presence in the OTC Division to dispensing doctors. Export opportunities in the Consumer and OTC Divisions.

  
Innovation

Improve access to our pipeline at the MCC in the Prescription, OTC and Hospital Divisions. In the Consumer and OTC Divisions extend formulations, pack variants and line extensions within our analgesia, energy and anti-histamine product range.

TRANSFORMATION

Maintaining our Level 4 score through a focus on:

Employment
Equity		   Preferential
Procurement		   Supplier
Development